BioCentury | Feb 27, 2021
Distillery Therapeutics

Trastuzumab-RNA polymerase inhibitor conjugate for breast cancer with low HER2 expression

...By Claire Quang, Staff Writer DISEASE CATEGORY: CancerINDICATION: Breast cancerAn antibody-drug conjugate comprising anti-HER2 antibody trastuzumab...
...inhibited growth with IC50 values 20-200 times lower than marketed ADC Kadcyla ado-trastuzumab emtansine, which conjugates trastuzumab...
...DM1. In a xenograft mouse model of TNBC with 17p loss and low HER2 expression, the trastuzumab-α-amanitin...
BioCentury | Feb 13, 2021
Product Development

Feb. 12 Quick Takes: G1’s first approval is first in class; plus Seagen, Denali, Roche and Takeda

...GmbH.Seagen’s Tuksya gains EU approvalThe European Commission approved Tuksya tucatinib from Seagen Inc. (NASDAQ:SGEN) plus trastuzumab...
BioCentury | Jan 29, 2021
Management Tracks

Kirk Raab, first BIO chair and early Genentech CEO, dies at 85

...cancer drugs, such as Rituxan rituximab and Herceptin trastuzumab...
BioCentury | Jan 27, 2021
Product Development

KSQ sets sights on the clinic as new CEO steps in

...Hemlibra emicizumab-kxwh. He was also involved in the launches of Herceptin trastuzumab, Perjeta pertuzumab and Kadcyla ado-trastuzumab...
...non-Hodgkin lymphoma (NHL) therapy.“What excites me and motivates me is novel therapies with transformational potential. Herceptin...
BioCentury | Jan 23, 2021
Emerging Company Profile

Technology showcase: BioCentury’s 2020 class of emerging companies

...NK cells conjugated with the anti-HER2 antibody trastuzumab...
BioCentury | Jan 21, 2021
Product Development

Jan. 20 Quick Takes: AZ, Daiichi get Enhertu approvals in gastric, breast cancer; plus EdiGene, Merck, Oxford, BMS and Omeros

...plc (LSE:AZN; NASDAQ:AZN) and Daiichi Sankyo Co. Ltd. (Tokyo:4568) said HER2-targeted antibody-drug conjugate (ADC) Enhertu fam-trastuzumab...
...advanced or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma patients who have received a prior trastuzumab-based...
BioCentury | Jan 16, 2021
Product Development

Zymeworks showcases >45% confirmed ORRs for anti-HER2 bispecific in biliary, gastroesophageal cancers

...data showing zanidatamab led to a confirmed objective response rate (ORR) of 47% in 15 Herceptin trastuzumab-naïve...
...HER2 domains as Herceptin and Perjeta pertuzumab from Roche (SIX:ROG; OTCQX:RHHBY).Zymeworks believes zanidatamab will be better than a Herceptin-Perjeta...
BioCentury | Dec 17, 2020
Deals

Dec. 16 Quick Takes: MacroGenics' margetuximab approved for breast cancer; plus sotorasib, Mesoblast, Cardior, Takeda, Allero

...have improved progression-free survival (PFS) versus Herceptin trastuzumab...
BioCentury | Dec 12, 2020
Product Development

Ipsen is casting a wider BD net under new CEO Loew

...company that you can’t carry and replace Herceptin...
BioCentury | Dec 12, 2020
Regulation

CHMP’s December opinions include restrictions for Veklury in COVID, support for Daiichi, Seagen breast cancer drugs

...or high-flow oxygen or other non-invasive ventilation at the start of treatment. The committee also backed Enhertu trastuzumab...
...ligand 1TNF – Tumor necrosis factorTROP2 (TACSTD2; EGP-1) – Tumor-associated calcium signal transducer 2 Sandi Wong Veklury, remdesivir (GS-5734) Enhertu, fam-trastuzumab...
Items per page:
1 - 10 of 1423